PCOS is one of the most common endocrine disorders affecting women and it is characterized by a combination of hyper-androgenism, chronic anovulation, and insulin resistance. While a significant progress has recently been made in the diagnosis for PCOS, the optimal infertility treatment remains to be determined. Two inositol isomers, myo-inositol (MI) and D-chiro-inositol (DCI) have been proven to be effective in PCOS treatment, by improving insulin resistance, serum androgen levels and many features of the metabolic syndrome. However, DCI alone, mostly when it is administered at high dosage, negatively affects oocyte quality, whereas the association MI/DCI, in a combination reproducing the plasma physiological ratio (40:1), represents a promising alternative in achieving better clinical results, by counteracting PCOS at both systemic and ovary level. © 2014, The American College of Clinical Pharmacology.

The rationale of the myo-inositol and D-chiro-inositol combined treatment for polycystic ovary syndrome / Dinicola, Simona; Tony T. Y., Chiu; Vittorio, Unfer; Gianfranco, Carlomagno; Bizzarri, Mariano. - In: THE JOURNAL OF CLINICAL PHARMACOLOGY. - ISSN 0091-2700. - STAMPA. - 54:10(2014), pp. 1079-1092. [10.1002/jcph.362]

The rationale of the myo-inositol and D-chiro-inositol combined treatment for polycystic ovary syndrome.

DINICOLA, SIMONA;BIZZARRI, Mariano
2014

Abstract

PCOS is one of the most common endocrine disorders affecting women and it is characterized by a combination of hyper-androgenism, chronic anovulation, and insulin resistance. While a significant progress has recently been made in the diagnosis for PCOS, the optimal infertility treatment remains to be determined. Two inositol isomers, myo-inositol (MI) and D-chiro-inositol (DCI) have been proven to be effective in PCOS treatment, by improving insulin resistance, serum androgen levels and many features of the metabolic syndrome. However, DCI alone, mostly when it is administered at high dosage, negatively affects oocyte quality, whereas the association MI/DCI, in a combination reproducing the plasma physiological ratio (40:1), represents a promising alternative in achieving better clinical results, by counteracting PCOS at both systemic and ovary level. © 2014, The American College of Clinical Pharmacology.
2014
polycystic ovarian syndrome; infertility; oocyte; embryo; inositol
01 Pubblicazione su rivista::01a Articolo in rivista
The rationale of the myo-inositol and D-chiro-inositol combined treatment for polycystic ovary syndrome / Dinicola, Simona; Tony T. Y., Chiu; Vittorio, Unfer; Gianfranco, Carlomagno; Bizzarri, Mariano. - In: THE JOURNAL OF CLINICAL PHARMACOLOGY. - ISSN 0091-2700. - STAMPA. - 54:10(2014), pp. 1079-1092. [10.1002/jcph.362]
File allegati a questo prodotto
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/699260
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 23
  • Scopus 80
  • ???jsp.display-item.citation.isi??? 71
social impact